Adaptive Biotechnologies Corporation (ADPT)
- Previous Close
2.3350 - Open
2.3100 - Bid 2.3900 x 1000
- Ask 2.4200 x 700
- Day's Range
2.2800 - 2.4798 - 52 Week Range
2.2800 - 9.0800 - Volume
2,316,184 - Avg. Volume
1,644,039 - Market Cap (intraday)
348.221M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5600 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.40
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
www.adaptivebiotech.comRecent News: ADPT
Performance Overview: ADPT
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADPT
Valuation Measures
Market Cap
351.12M
Enterprise Value
103.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.05
Price/Book (mrq)
1.14
Enterprise Value/Revenue
0.61
Enterprise Value/EBITDA
-0.55
Financial Highlights
Profitability and Income Statement
Profit Margin
-132.28%
Return on Assets (ttm)
-16.60%
Return on Equity (ttm)
-58.34%
Revenue (ttm)
170.28M
Net Income Avi to Common (ttm)
-225.25M
Diluted EPS (ttm)
-1.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
346.4M
Total Debt/Equity (mrq)
74.42%
Levered Free Cash Flow (ttm)
-81.95M